Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19

被引：0

作者：

Sutanto, Samuel Theodorus ^{[1
]}

Sinto, Robert ^{[2
]}

Pasaribu, Adeline ^{[2
]}

Shakinah, Sharifah ^{[2
]}

机构：

[1] Univ Kristen Krida Wacana, Fac Med, Jakarta, Indonesia

[2] Univ Indonesia, Dept Internal Med, Div Trop & Infect Dis, Fac Med,Cipto Mangunkusumo Hosp, Jl Diponegoro 71, Jakarta 10430, Indonesia

来源：

ACTA MEDICA INDONESIANA | 2022年 / 54卷 / 04期

关键词：

antiviral; COVID-19; molnupiravir; nirmatrelvir; ritonavir; SARS-CoV-2;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Coronavirus disease 2019 (COVID-19) is a respiratory tract disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With the complexity of multimorbidity in Indonesia, it is crucial to find another line of antiviral for COVID-19. This article aims to review two antivirals, molnupiravir and nirmatrelvir/ ritonavir, that have been studied extensively in treating COVID-19 with promising results, and their availability in Indonesia. Molnupiravir and nirmatrelvir/ritonavir are two of many repurposed drugs in clinical trials, which have been reported to have a mechanism in quick clearance of SARS-CoV-2, reduction in viral load, and fast symptoms recovery time in phase 1 and 2 clinical trials. Phase 2/3 clinical study in COVID-19 patients without any indication for hospitalization showed that molnupiravir and nirmatrelvir/ritonavir significantly reduced the risk of hospitalization and death.

引用

页码：638 / 644

页数：7

共 24 条

[1] Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients [J].

Bernal, A. Jayk ;

da Silva, M. M. Gomes ;

Musungaie, D. B. ;

Kovalchuk, E. ;

Gonzalez, A. ;

Delos Reyes, V ;

Martin-Quiros, A. ;

Caraco, Y. ;

Williams-Diaz, A. ;

Brown, M. L. ;

Du, J. ;

Pedley, A. ;

Assaid, C. ;

Strizki, J. ;

Grobler, J. A. ;

Shamsuddin, H. H. ;

Tipping, R. ;

Wan, H. ;

Paschke, A. ;

Butterton, J. R. ;

Johnson, M. G. ;

De Anda, C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (06) :509-520

[2]

BPOM, 2021, Badan POM terbitkan emergency use authorization vaksin AstraZeneca, Badan Pengawas Obat dan Makanan

[3]

Burhan E, 2022, PEDOMAN TATALAKSANA, P15

[4] An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment [J].

Drozdzal, Sylwester ;

Rosik, Jakub ;

Lechowicz, Kacper ;

Machaj, Filip ;

Szostak, Bartosz ;

Przybycinski, Jaroslaw ;

Lorzadeh, Shahrokh ;

Kotfis, Katarzyna ;

Ghavami, Saeid ;

Los, Marek J. .

DRUG RESISTANCE UPDATES, 2021, 59

[5]

Fischer William, 2021, medRxiv, DOI 10.1101/2021.06.17.21258639

[6] A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus [J].

Fischer, William A., II ;

Eron, Joseph J., Jr. ;

Holman, Wayne ;

Cohen, Myron S. ;

Fang, Lei ;

Szewczyk, Laura J. ;

Sheahan, Timothy P. ;

Baric, Ralph ;

Mollan, Katie R. ;

Wolfe, Cameron R. ;

Duke, Elizabeth R. ;

Azizad, Masoud M. ;

Borroto-Esoda, Katyna ;

Wohl, David A. ;

Coombs, Robert W. ;

Loftis, Amy James ;

Alabanza, Paul ;

Lipansky, Felicia ;

Painter, Wendy P. .

SCIENCE TRANSLATIONAL MEDICINE, 2022, 14 (628)

[7] Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 [J].

Hammond, Jennifer ;

Leister-Tebbe, Heidi ;

Gardner, Annie ;

Abreu, Paula ;

Bao, Weihang ;

Wisemandle, Wayne ;

Baniecki, MaryLynn ;

Hendrick, Victoria M. ;

Damle, Bharat ;

Simon-Campos, Abraham ;

Pypstra, Rienk ;

Rusnak, James M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (15) :1397-1408

[8] Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark? [J].

Hung, Yuan-Pin ;

Lee, Jen-Chieh ;

Chiu, Chun-Wei ;

Lee, Ching-Chi ;

Tsai, Pei-Jane ;

Hsu, I-Lin ;

Ko, Wen-Chien .

ANTIBIOTICS-BASEL, 2022, 11 (02)

[9] Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19 [J].

Imran, Mohd ;

Kumar Arora, Mandeep ;

Asdaq, Syed Mohammed Basheeruddin ;

Khan, Shah Alam ;

Alaqel, Saleh I. ;

Alshammari, Mohammed Kanan ;

Alshehri, Mohammed M. ;

Alshrari, Ahmed Subeh ;

Mateq Ali, Alreshidi ;

Al-shammeri, Ahmed Muteb ;

Alhazmi, Bushra Dhuhayyan ;

Harshan, Aishah Ali ;

Alam, Md. Tauquir ;

Abida .

MOLECULES, 2021, 26 (19)

[10]

John Hopkins Univeristy, 2022, COVID 19 DASHB CTR S

← 1 2 3 →